Form 4: Akoya Biosciences Completes Merger with Quanterix, Director Disposes of Shares and Options

Akoya Biosciences, Inc. has completed its merger with Quanterix Corporation, resulting in the disposition of common stock and termination of certain stock options for Director Myla Lai-Goldman.

Summary

• Akoya Biosciences, Inc. merged with Wellfleet Merger Sub, Inc., a wholly-owned subsidiary of Quanterix Corporation, on July 8, 2025, with Akoya surviving as a wholly-owned subsidiary of Quanterix.
• Each outstanding share of Akoya common stock was converted into the right to receive 0.1461 shares of Quanterix common stock and $0.38 in cash.
• Director Myla Lai-Goldman disposed of 20,000 shares of Akoya Common Stock as part of the merger.
• Myla Lai-Goldman also disposed of 175,864 stock options, including 38,993 options with an exercise price of $18.1, 30,549 options at $11.24, 56,322 options at $5.7, and 50,000 options at $2.01.
• Stock options with an exercise price equal to or greater than the Per Share Merger Consideration were automatically terminated and cancelled for no consideration.

Sentiment

Score: 7

Explanation: The completion of a merger is generally a positive step for the acquiring company and provides a defined outcome for the acquired company's shareholders. While some options were terminated for no consideration, this is a specific outcome of the merger terms, not necessarily a negative for the overall strategic move. The transaction itself is a neutral reporting of a completed event, but the underlying merger is a strategic positive.

Positives

• The merger provides Akoya shareholders with a combination of Quanterix stock and cash, offering continued equity participation in the combined entity and immediate liquidity.
• The completion of the merger signifies a strategic consolidation, potentially leading to synergies and a stronger market position for the combined entity.

Negatives

• Stock options with exercise prices equal to or greater than the merger consideration were terminated for no consideration, indicating a loss of value for holders of those specific options.

Future Outlook

NA

Industry Context

The merger of Akoya Biosciences with Quanterix Corporation represents a consolidation within the life sciences and biotechnology sector, specifically in the area of precision medicine and proteomics. Such mergers often aim to combine complementary technologies, expand market reach, and achieve operational efficiencies, reflecting a broader trend of strategic alliances and acquisitions in the industry to drive innovation and growth.

Stakeholder Impact

• Shareholders of Akoya Biosciences: Received a combination of Quanterix stock and cash for their shares.
• Option Holders of Akoya Biosciences: Options with exercise prices at or above the merger consideration were terminated for no value.
• Employees of Akoya Biosciences: Akoya is now a wholly-owned subsidiary of Quanterix, implying potential integration and changes to employment terms or structure.
• Quanterix Corporation: Acquired Akoya Biosciences, expanding its market presence and technology portfolio.

Next Steps

• Akoya Biosciences, Inc. will operate as a wholly-owned subsidiary of Quanterix Corporation.
• Further integration activities between Akoya Biosciences and Quanterix Corporation are expected.

Key Dates

Keywords

Akoya Biosciences, Quanterix Corporation, Merger, SEC Form 4, Beneficial Ownership, Stock Disposition, Option Termination, Corporate Acquisition, Biotechnology, Life Sciences